$2.13
1.39%
Nasdaq, Jul 11, 10:17 pm CET
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Cassava Sciences, Inc. Stock price

$2.13
+0.04 1.91% 1M
-0.60 21.98% 6M
-0.23 9.75% YTD
-8.86 80.62% 1Y
-21.21 90.87% 3Y
-1.51 41.48% 5Y
-9.77 82.10% 10Y
-31.04 93.58% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.03 1.39%
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Key metrics

Basic
Market capitalization
$102.9m
Enterprise Value
$-14.4m
Net debt
positive
Cash
$117.3m
Shares outstanding
48.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.8
Financial Health
Equity Ratio
92.5%
Return on Equity
-16.7%
ROCE
-114.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-145.2m | -
EBIT
$-146.1m | $-36.4m
Net Income
$-72.8m | $-27.1m
Free Cash Flow
$-109.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-48.2% | -
EBIT
-47.0% | 74.3%
Net Income
-51.9% | -11.3%
Free Cash Flow
-24.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-2.3
Short interest
17.2%
Employees
30
Rev per Employee
$0.0
Show more

Is Cassava Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Cassava Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cassava Sciences, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Cassava Sciences, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Cassava Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 79 79
399% 399%
-
- Research and Development Expense 67 67
20% 20%
-
-145 -145
48% 48%
-
- Depreciation and Amortization 0.92 0.92
36% 36%
-
EBIT (Operating Income) EBIT -146 -146
47% 47%
-
Net Profit -73 -73
52% 52%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cassava Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cassava Sciences, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervo...
Neutral
GlobeNewsWire
2 months ago
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy,  and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on develo...
Neutral
GlobeNewsWire
3 months ago
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Me...
More Cassava Sciences, Inc. News

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Head office United States
CEO Mr. Barry
Employees 30
Founded 1998
Website www.cassavasciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today